within Pharmacolibrary.Drugs.ATC.R;

model R01AX30
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 12 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.14 / 1000000,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>The combination of xylometazoline, a topical nasal decongestant (alpha-adrenergic agonist), and dexamethasone, a corticosteroid with anti-inflammatory properties, is used in intranasal preparations to reduce nasal congestion and inflammation associated with rhinitis or sinusitis. It is not widely approved as a fixed drug combination in major markets, but is referenced under ATC code R01AX30.</p><h4>Pharmacokinetics</h4><p>No direct pharmacokinetic (PK) studies on the combination product exist. Estimates are based on published data of each substance administered intranasally in healthy adults.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R01AX30;
